Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy

NCT04227028 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04227028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04227028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 9, 2020
Completion date
March 25, 2027
Enrollment
5 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced lung non-small cell carcinoma, metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8